280 related articles for article (PubMed ID: 32750605)
21. Preparation of superparamagnetic iron oxide/doxorubicin loaded chitosan nanoparticles as a promising glioblastoma theranostic tool.
Gholami L; Tafaghodi M; Abbasi B; Daroudi M; Kazemi Oskuee R
J Cell Physiol; 2019 Feb; 234(2):1547-1559. PubMed ID: 30145790
[TBL] [Abstract][Full Text] [Related]
22. Modified methods of nanoparticles synthesis in pH-sensitive nano-carriers production for doxorubicin delivery on MCF-7 breast cancer cell line.
Hamidu A; Mokrish A; Mansor R; Razak ISA; Danmaigoro A; Jaji AZ; Bakar ZA
Int J Nanomedicine; 2019; 14():3615-3627. PubMed ID: 31190815
[No Abstract] [Full Text] [Related]
23. Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer.
Yang X; Shang P; Ji J; Malichewe C; Yao Z; Liao J; Du D; Sun C; Wang L; Tang YJ; Guo X
Mol Pharm; 2022 Jan; 19(1):2-17. PubMed ID: 34910493
[TBL] [Abstract][Full Text] [Related]
24. Chitosan-tripolyphosphate nanoparticles functionalized with a pH-responsive amphiphile improved the in vitro antineoplastic effects of doxorubicin.
Nogueira-Librelotto DR; Scheeren LE; Vinardell MP; Mitjans M; Rolim CMB
Colloids Surf B Biointerfaces; 2016 Nov; 147():326-335. PubMed ID: 27543694
[TBL] [Abstract][Full Text] [Related]
25. Benzylguanidine and Galactose Double-Conjugated Chitosan Nanoparticles with Reduction Responsiveness for Targeted Delivery of Doxorubicin to CXCR 4 Positive Tumors.
Kong F; Tang C; Yin C
Bioconjug Chem; 2020 Oct; 31(10):2446-2455. PubMed ID: 32991164
[TBL] [Abstract][Full Text] [Related]
26. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
[TBL] [Abstract][Full Text] [Related]
27. Co-delivery of doxorubicin and siRNA by all-trans retinoic acid conjugated chitosan-based nanocarriers for multiple synergistic antitumor efficacy.
Liu C; Tang C; Yin C
Carbohydr Polym; 2022 May; 283():119097. PubMed ID: 35153031
[TBL] [Abstract][Full Text] [Related]
28. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
[TBL] [Abstract][Full Text] [Related]
29. Macrophage membrane-camouflaged pH-sensitive nanoparticles for targeted therapy of oral squamous cell carcinoma.
Yang L; Li H; Luo A; Zhang Y; Chen H; Zhu L; Yang D
J Nanobiotechnology; 2024 Apr; 22(1):168. PubMed ID: 38610015
[TBL] [Abstract][Full Text] [Related]
30. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
[TBL] [Abstract][Full Text] [Related]
31. Preparation of Doxorubicin-Loaded Carboxymethyl-β-Cyclodextrin/Chitosan Nanoparticles with Antioxidant, Antitumor Activities and pH-Sensitive Release.
Mi Y; Zhang J; Tan W; Miao Q; Li Q; Guo Z
Mar Drugs; 2022 Apr; 20(5):. PubMed ID: 35621929
[TBL] [Abstract][Full Text] [Related]
32. Genipin-crosslinked catechol-chitosan mucoadhesive hydrogels for buccal drug delivery.
Xu J; Strandman S; Zhu JX; Barralet J; Cerruti M
Biomaterials; 2015 Jan; 37():395-404. PubMed ID: 25453967
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
[TBL] [Abstract][Full Text] [Related]
34. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
35. A strategy for oral chemotherapy via dual pH-sensitive polyelectrolyte complex nanoparticles to achieve gastric survivability, intestinal permeability, hemodynamic stability and intracellular activity.
Deng L; Dong H; Dong A; Zhang J
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):107-17. PubMed ID: 26515259
[TBL] [Abstract][Full Text] [Related]
36. Diselenide-crosslinked carboxymethyl chitosan nanoparticles for doxorubicin delivery: Preparation and in vivo evaluation.
Wang J; Liu J; Lu DQ; Chen L; Yang R; Liu D; Zhang B
Carbohydr Polym; 2022 Sep; 292():119699. PubMed ID: 35725216
[TBL] [Abstract][Full Text] [Related]
37. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
Han HS; Thambi T; Choi KY; Son S; Ko H; Lee MC; Jo DG; Chae YS; Kang YM; Lee JY; Park JH
Biomacromolecules; 2015 Feb; 16(2):447-56. PubMed ID: 25565417
[TBL] [Abstract][Full Text] [Related]
38. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy.
Wu J; Tang C; Yin C
Acta Biomater; 2017 Jan; 47():81-90. PubMed ID: 27729232
[TBL] [Abstract][Full Text] [Related]
39. Co-delivery of doxorubicin and CRISPR/Cas9 or RNAi-expressing plasmid by chitosan-based nanoparticle for cancer therapy.
Li Q; Lv X; Tang C; Yin C
Carbohydr Polym; 2022 Jul; 287():119315. PubMed ID: 35422284
[TBL] [Abstract][Full Text] [Related]
40. Simply constructed chitosan nanocarriers with precise spatiotemporal control for efficient intracellular drug delivery.
Kong M; Zuo Y; Wang M; Bai X; Feng C; Chen X
Carbohydr Polym; 2017 Aug; 169():341-350. PubMed ID: 28504154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
